GSK bags Tesaro for $5B as it leaps back into commercial oncology and beefs up cancer drug pipeline
GlaxoSmithKline has struck a deal to buy Tesaro $TSRO in a $5.1 billion deal that will vault the pharma giant into the commercial oncology market …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
